中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

60 records (took 0.038 seconds)

    PROGNOSTIC MARKERS AND THERAPEUTIC TARGETS FOR LUNG CANCER
    11.
    发明申请
    PROGNOSTIC MARKERS AND THERAPEUTIC TARGETS FOR LUNG CANCER 审中-公开
    预测肺癌的预后指标和治疗目标

    公开(公告)号：WO2008023840A2

    公开(公告)日：2008-02-28

    申请号：PCT/JP2007066825

    申请日：2007-08-23

    Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

    Inventor： NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

    IPC: C12Q1/68

    CPC classification number: C12Q1/6886 ,  C12Q2600/158

    Abstract: The present invention provides a diagnostic marker to detecting lung cancer. In particular, the present invention provides lung cancer marker genes i.e. KIF4A, MAPJD, NPTX, or FGFR1OP. The present invention further provides methods and kit for identifying compounds for treating lung cancer as well as methods for predicting a prognosis or diagnosis of lung cancer. In particular, the present invention provides methods and kits for identifying inhibitors of the interaction between KIF4A/ZNF549, KIF4A/ZNF553, MAPJD/MYC, or FGFR1OP/WRNIP1 which find utility in the treatment and prevention of lung. Alternatively, the present invention provides MAPJD associated with HAT complex as therapeutic target.

    Abstract translation: 本发明提供了检测肺癌的诊断标记。 具体而言，本发明提供肺癌标志物基因，即KIF4A，MAPJD，NPTX或FGFR1OP。 本发明进一步提供了鉴定用于治疗肺癌的化合物的方法和试剂盒以及预测肺癌预后或诊断的方法。 具体而言，本发明提供了用于鉴定可用于治疗和预防肺的KIF4A / ZNF549，KIF4A / ZNF553，MAPJD / MYC或FGFR1OP / WRNIP1之间相互作用抑制剂的方法和试剂盒。 或者，本发明提供与作为治疗靶标的HAT复合物相关的MAPJD。

    METHOD OF DIAGNOSING SMALL CELL LUNG CANCER
    12.
    发明申请
    METHOD OF DIAGNOSING SMALL CELL LUNG CANCER 审中-公开
    诊断小细胞肺癌的方法

    公开(公告)号：WO2007013665A3

    公开(公告)日：2007-07-05

    申请号：PCT/JP2006315254

    申请日：2006-07-26

    Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

    Inventor： NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

    IPC: C12Q1/68 ,  C12N15/113

    CPC classification number: C12N15/1135 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/136

    Abstract: Objective methods for detecting and diagnosing small cell lung cancer (SCLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of an SCLC-associated gene that discriminates between SCLC cells and normal cells. In another embodiment, the diagnostic method involves determining the expression level of an SCLC-associated gene that distinguishes two major histological types of lung cancer, non-small cell lung cancer (NSCLC) and SCLC. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of small cell lung cancer, methods of treating small cell lung cancer and method for vaccinating a subject against small cell lung cancer. Furthermore, the present invention provides chemotherapy resistant lung cancer- or SCLC-associated genes as diagnostic markers and/or molecular targets for therapeutic agent for these cancers. These genes are up-regulated in chemoresistant lung cancer or SCLC. Accordingly, chemoresistant lung cancer or SCLC can be predicted using expression level of the genes as diagnostic markers. As the result, any adverse effects caused by ineffective chemotherapy can be avoided, and more suitable and effective therapeutic strategy can be selected.

    Abstract translation: 本文描述了用于检测和诊断小细胞肺癌（SCLC）的客观方法。 在一个实施方案中，诊断方法包括确定区分SCLC细胞和正常细胞的SCLC相关基因的表达水平。 在另一个实施方案中，诊断方法涉及确定区分肺癌，非小细胞肺癌（NSCLC）和SCLC两种主要组织学类型的SCLC相关基因的表达水平。 最后，本发明提供筛选用于治疗小细胞肺癌的治疗剂的方法，治疗小细胞肺癌的方法和用于针对小细胞肺癌接种受试者的方法。 此外，本发明提供化疗耐受性肺癌或SCLC相关基因作为这些癌症的治疗剂的诊断标记和/或分子靶标。 这些基因在化学抗性肺癌或SCLC中上调。 因此，可以使用基因的表达水平作为诊断标记来预测化学抗性肺癌或SCLC。 结果，可以避免由无效化疗引起的任何副作用，并且可以选择更合适和有效的治疗策略。

    METHOD OF DIAGNOSING ESOPHAGEAL CANCER
    13.
    发明申请
    METHOD OF DIAGNOSING ESOPHAGEAL CANCER 审中-公开
    诊断食管癌的方法

    公开(公告)号：WO2007013671A2

    公开(公告)日：2007-02-01

    申请号：PCT/JP2006315342

    申请日：2006-07-26

    Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

    Inventor： NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

    IPC: C12Q1/68

    CPC classification number: C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  Y10T436/25

    Abstract: In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. A detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. These genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. Additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. Among the candidate molecular target genes, a Homo sapiens epithelial cell transforming sequence 2 oncogene (ECT2) and a cell division cycle 45, S. cerevisiae, homolog-like (CDC45L) are further characterized. Treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells. Thus, the data herein provide valuable information for identifying diagnostic systems and therapeutic target molecules for esophageal cancer. Furthermore, the present inventors have identified DKK1 as a potential biomarker for diagnosis of cancer such as lung and esophageal cancers as well as prediction of the poor prognosis of the patients with these diseases. DKK1 was specifically over-expressed in most lung and esophageal cancer tissues the present inventors examined, and was elevated in the sera of a large proportion of patients with these tumors. DKK1, combined with other tumor markers, could significantly improve the sensitivity of cancer diagnosis. Moreover, this molecule is also a likely candidate for development of therapeutic approaches such as antibody therapy.

    Abstract translation: 为了鉴定涉及食管癌发生的分子以及可用于诊断标志物以及新药和免疫治疗目标的分子，构建了代表32,256个基因的cDNA微阵列，分析了19例食管鳞状细胞癌（ESCCS）的表达谱 ）通过激光捕获显微切割纯化。 本文公开了在食管癌中显着上调或下调的基因组的详细全基因组数据库。 这些基因可用于治疗药物或免疫治疗以及肿瘤标志物的开发。 此外，本文公开了与淋巴结转移和手术后复发相关的基因。 在候选分子靶基因中，进一步表征了人类上皮细胞转化序列2致癌基因（ECT2）和细胞分裂周期45，酿酒酵母，同系物样（CDC45L）。 用ECT2或CDC45L的小干扰RNA（siRNA）处理ESCC细胞抑制癌细胞的生长。 因此，本文的数据提供了用于鉴定诊断系统和用于食管癌的治疗靶分子的有价值的信息。 此外，本发明人鉴定了DKK1作为肺癌，食管癌等癌症诊断用潜在生物标志物，并预测了这些疾病患者的预后差。 本发明人检查的大多数肺癌和食管癌组织中DKK1被特异性过度表达，并且在大量患有这些肿瘤的患者的血清中升高。 DKK1与其他肿瘤标志物结合可显着提高癌症诊断的敏感性。 此外，该分子也是开发抗体治疗等治疗方法的可能候选者。

    COMPOSITIONS AND METHODS FOR TREATING LUNG CANCER
    15.
    发明申请
    COMPOSITIONS AND METHODS FOR TREATING LUNG CANCER 审中-公开
    用于治疗肺癌的组合物和方法

    公开(公告)号：WO2005089735A3

    公开(公告)日：2006-03-02

    申请号：PCT/JP2005005621

    申请日：2005-03-18

    Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

    Inventor： NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

    IPC: C12N15/113 ,  G01N33/574 ,  C12N15/11

    CPC classification number: C12N15/113 ,  C12N15/1138 ,  C12N2310/111 ,  C12N2310/53 ,  G01N33/57423

    Abstract: The invention features a method for inhibiting growth of a cancer cell by contacting the cell with a composition of a PKP3, CDCA1, CDCA8, DLX5, URLC11 or NPTX1 siRNA. Methods of treating cancer are also within the invention. The invention also features products, including nucleic acid sequences and vectors as well as to compositions comprising them, useful in the provided methods. The invention also provides a method for inhibiting of tumor cell, for example lung cancer cell, particularly NSCLC.

    Abstract translation: 本发明的特征在于通过使细胞与PKP3，CDCA1，CDCA8，DLX5，URLC11或NPTX1 siRNA的组合物接触来抑制癌细胞生长的方法。 治疗癌症的方法也在本发明的范围内。 本发明还包括可用于所提供的方法的产品，包括核酸序列和载体以及包含它们的组合物。 本发明还提供了抑制肿瘤细胞的方法，例如肺癌细胞，特别是NSCLC。

Patent Agency Ranking